blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2313436

EP2313436 - AMINO ACID SEQUENCES DIRECTED AGAINST MULTITARGET SCAVENGER RECEPTORS AND POLYPEPTIDES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.10.2015
Database last updated on 17.07.2024
Most recent event   Tooltip22.06.2018Lapse of the patent in a contracting state
New state(s): MK		published on 25.07.2018  [2018/30]
Applicant(s)For all designated states
Ablynx N.V.
Technologiepark 21
9052 Ghent-Zwijnaarde / BE
[2014/48]
Former [2011/17]For all designated states
Ablynx NV
Technologiepark 21
9052 Ghent-Zwijnaarde / BE
Inventor(s)01 / SARAIVA, Maria Joao
R Bessa Leite 856 Hab 31
P-4150 Porto / PT
02 / VANLANDSCHOOT, Peter
Markettestraat 20-A
B-9881 Bellem / BE
03 / DOLK, Edward
Aldo van Eyckplantsoen 95
NL-3544 LD Utrecht / NL
04 / DE BRUIN, Renée
Raamstraat 26
NL-3513 EZ Utrecht / NL
 [2014/47]
Former [2011/24]01 / SARAIVA, Maria Joao
R Bessa Leite 856 Hab 31
P-4150 Porto / PT
02 / VANLANDSCHOOT, Peter
Markettestraat 20-A
B-9881 Bellem / BE
03 / DOLK, Edward
Aldo van Eyckplantsoen 95
NL-3544 LD Utrecht / NL
04 / DE BRUIN, Renee
Titus van Rijnstraat 275
NL-1058 GB Amsterdam / NL
Former [2011/17]01 / SARAIVA, Maria Joao
R Bessa Leite 856 Hab 31
P-4150 Porto / PT
02 / VANLANDSCHOOT, Peter
Markettestraat 20-A
B-9881 Bellem / BE
03 / DOLK, Edward
Aldo van Eyckplantsoen 95
NL-3544 LD Utrecht / NL
04 / DE BRUIN, Renee
Raamstraat 26
NL-3513 EZ Utrecht / NL
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2014/48]
Former [2011/17]HOFFMANN EITLE
Patent- und Rechtsanwälte Arabellastraße 4
81925 München / DE
Application number, filing date09780925.522.07.2009
[2011/17]
WO2009EP59424
Priority number, dateUS20080082614P22.07.2008         Original published format: US 82614 P
[2011/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010010119
Date:28.01.2010
Language:EN
[2010/04]
Type: A1 Application with search report 
No.:EP2313436
Date:27.04.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 28.01.2010 takes the place of the publication of the European patent application.
[2011/17]
Type: B1 Patent specification 
No.:EP2313436
Date:26.11.2014
Language:EN
[2014/48]
Search report(s)International search report - published on:EP28.01.2010
ClassificationIPC:C07K16/28
[2011/17]
CPC:
C07K16/2803 (EP,US); A61P19/02 (EP); A61P25/28 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61P9/10 (EP);
C07K2317/22 (EP,US); C07K2319/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/17]
TitleGerman:GEGEN MULTITARGET-SCAVENGER-REZEPTOREN UND POLYPEPTIDE GERICHTETE AMINOSÄURESEQUENZEN[2011/17]
English:AMINO ACID SEQUENCES DIRECTED AGAINST MULTITARGET SCAVENGER RECEPTORS AND POLYPEPTIDES[2011/17]
French:SÉQUENCES D ACIDES AMINÉS DIRIGÉES CONTRE DES RÉCEPTEURS DE DÉSACTIVEURS MULTICIBLES ET POLYPEPTIDES[2011/17]
Entry into regional phase03.02.2011National basic fee paid 
03.02.2011Designation fee(s) paid 
03.02.2011Examination fee paid 
Examination procedure03.02.2011Examination requested  [2011/17]
18.04.2011Amendment by applicant (claims and/or description)
23.03.2012Despatch of a communication from the examining division (Time limit: M06)
02.10.2012Reply to a communication from the examining division
11.02.2014Cancellation of oral proceeding that was planned for 13.02.2014
13.02.2014Date of oral proceedings (cancelled)
30.06.2014Communication of intention to grant the patent
14.10.2014Fee for grant paid
14.10.2014Fee for publishing/printing paid
14.10.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.03.2012
Opposition(s)27.08.2015No opposition filed within time limit [2015/45]
Fees paidRenewal fee
28.07.2011Renewal fee patent year 03
25.07.2012Renewal fee patent year 04
24.07.2013Renewal fee patent year 05
08.07.2014Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.07.2009
AT26.11.2014
BE26.11.2014
BG26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
MC26.11.2014
MK26.11.2014
MT26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SI26.11.2014
SK26.11.2014
SM26.11.2014
TR26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
LU22.07.2015
[2018/30]
Former [2017/46]HU22.07.2009
AT26.11.2014
BE26.11.2014
BG26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
MC26.11.2014
MT26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SI26.11.2014
SK26.11.2014
SM26.11.2014
TR26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
LU22.07.2015
Former [2017/38]HU22.07.2009
AT26.11.2014
BG26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
MC26.11.2014
MT26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SI26.11.2014
SK26.11.2014
SM26.11.2014
TR26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
LU22.07.2015
Former [2017/21]AT26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
MC26.11.2014
MT26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SI26.11.2014
SK26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
LU22.07.2015
Former [2016/15]AT26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
MC26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SI26.11.2014
SK26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
LU22.07.2015
Former [2016/13]AT26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
MC26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SI26.11.2014
SK26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2016/12]AT26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SI26.11.2014
SK26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2016/03]AT26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
IT26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SK26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/37]AT26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
PL26.11.2014
RO26.11.2014
SE26.11.2014
SK26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/36]AT26.11.2014
CY26.11.2014
CZ26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
RO26.11.2014
SE26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/35]AT26.11.2014
CY26.11.2014
DK26.11.2014
EE26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
SE26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/26]AT26.11.2014
CY26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
SE26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/25]AT26.11.2014
ES26.11.2014
FI26.11.2014
HR26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
SE26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/24]ES26.11.2014
FI26.11.2014
HR26.11.2014
LT26.11.2014
LV26.11.2014
NL26.11.2014
SE26.11.2014
NO26.02.2015
GR27.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/23]ES26.11.2014
FI26.11.2014
LT26.11.2014
NL26.11.2014
NO26.02.2015
IS26.03.2015
PT26.03.2015
Former [2015/22]LT26.11.2014
NO26.02.2015
PT26.03.2015
Former [2015/21]LT26.11.2014
NO26.02.2015
Former [2015/20]LT26.11.2014
Cited inInternational search[Y]WO2007109747  (WYETH CORP [US], et al) [Y] 1-15 * page 1, paragraph 3 - page 59, paragraph 2 *;
 [Y]WO2007109749  (WYETH CORP [US], et al) [Y] 1-15 * page 4 - page 10; example 29 *;
 [Y]US2003143226  (KOBAYASHI YUKO [JP], et al) [Y] 1,15 * page 2, paragraph 19 - page 9, paragraph 155 *;
 [Y]WO2006079372  (ABLYNX NV [BE], et al) [Y] 1-15 * page 12 - page 38 * * page 79 - page 135; examples 1-21 *;
 [Y]  - BRO S ET AL, "A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 201, no. 2, ISSN 0021-9150, (200812), pages 274 - 280, (20080216), XP025780373 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.atherosclerosis.2008.01.015
 [Y]  - LUTTERLOH EMILY C ET AL, "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection", CRITICAL CARE, BIOMED CENTRAL LTD., LONDON, GB, (20071106), vol. 11, no. 6, ISSN 1364-8535, page R122, XP021041366 [Y] 1-15 * the whole document *
 [Y]  - ABD SEROTEC, "DATASHEET MCA1322T", (2007), URL: http://www.abdserotec.com/catalog/datasheetPdf.ashx?ProductID=143497&EntityID=0, (20091030), XP002553159 [Y] 1,15 * the whole document *
 [Y]  - ARBABI GHAHROUDI M ET AL, "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (19970915), vol. 414, no. 3, ISSN 0014-5793, pages 521 - 526, XP004261105 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0014-5793(97)01062-4
 [Y]  - HOLLIGER PHILIPP ET AL, "Engineered antibody fragments and the rise of single domains", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20050901), vol. 23, no. 9, ISSN 1087-0156, pages 1126 - 1136, XP008076746 [Y] 1-15 * page 1127 - page 1128 *

DOI:   http://dx.doi.org/10.1038/nbt1142
 [Y]  - REVETS H ET AL, "Nanobodies as novel agents for cancer therapy", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, (20050101), vol. 5, no. 1, ISSN 1471-2598, pages 111 - 124, XP009076361 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1517/14712598.5.1.111
 [Y]  - HULSTEIN JANINE J J ET AL, "A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS 13 deficiency and von Willebrand disease type 2B", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20051101), vol. 106, no. 9, ISSN 0006-4971, pages 3035 - 3042, XP002434260 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood-2005-03-1153
 [Y]  - LUE L-F ET AL, "Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimer's DiseaseSE", CURRENT DRUG TARGETS. CNS & NEUROLOGICAL DISORDERS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, (20050601), vol. 4, no. 3, ISSN 1568-007X, pages 249 - 266, XP009058262 [Y] 4,15 * page 261 *

DOI:   http://dx.doi.org/10.2174/1568007054038210
 [Y]  - BUCCIARELLI L G ET AL, "RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, (20020101), vol. 59, no. 7, ISSN 1420-682X, pages 1117 - 1128, XP001181919 [Y] 4,15 * page 1121 *

DOI:   http://dx.doi.org/10.1007/s00018-002-8491-x
 [Y]  - DEANE RASHID ET AL, "RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier.", STROKE; A JOURNAL OF CEREBRAL CIRCULATION NOV 2004, (200411), vol. 35, no. 11 Suppl 1, ISSN 1524-4628, pages 2628 - 2631, XP002553160 [Y] 4,15 * page 2630 *

DOI:   http://dx.doi.org/
 [Y]  - YAN SHI DU ET AL, "Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20000601), vol. 6, no. 6, ISSN 1078-8956, pages 643 - 651, XP002316616 [Y] 4,15 * page 644 - page 647 *

DOI:   http://dx.doi.org/10.1038/76216
 [Y]  - HUSEMANN JENS ET AL, "Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system.", GLIA NOV 2002, (200211), vol. 40, no. 2, ISSN 0894-1491, pages 195 - 205, XP002553161 [Y] 15 * page 200, column 2 - page 202, column 2 *

DOI:   http://dx.doi.org/10.1002/glia.10148
Examination   - MONTEIRO ET AL, "In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE)", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20060612), vol. 580, no. 14, doi:10.1016/J.FEBSLET.2006.05.020, ISSN 0014-5793, pages 3451 - 3456, XP005511106

DOI:   http://dx.doi.org/10.1016/j.febslet.2006.05.020
    - SOUSA ET AL, "Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways.", JOURNAL OF NEUROSCIENCE, (20011001), vol. 21, no. 19, ISSN 0270-6474, pages 7576 - 7586, XP055021746
    - STURCHLER EMMANUEL ET AL, "Site-specific blockade of RAGE-V-d prevents amyloid-beta oligomer neurotoxicity", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, (20080501), vol. 28, no. 20, doi:10.1523/JNEUROSCI.4878-07.2008, ISSN 0270-6474, pages 5149 - 5158, XP002541369

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.4878-07.2008
    - SOUSA MONICA MENDES ET AL, "Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PALHOLOGY, INC, (20000701), vol. 80, no. 7, ISSN 0023-6837, pages 1101 - 1110, XP002316617
by applicantWO2008020079
 WO03054016
 WO0029004
 WO0027435
 WO9822141
 WO0177137
 WO2007112940
 WO9942077
 WO2006040153
 WO2006122825
 WO9404678
 WO2004081026
    - PRESTA, ADV. DRUG DELIV. REV., (2006), vol. 58, no. 5-6, pages 640 - 56
    - LEVIN; WEISS, MOL. BIOSYST., (2006), vol. 2, no. 1, pages 49 - 57
    - IRVING ET AL., J. IMMUNOL. METHODS, (2001), vol. 248, no. 1-2, pages 31 - 45
    - SCHMITZ ET AL., PLACENTA, (2000), vol. 21, no. A, pages 106 - 12
    - GONZALES ET AL., TUMOUR BIOL., (2005), vol. 26, no. 1, pages 31 - 43
    - NATURE BIOTECHNOLOGY, (2005), vol. 23, no. 9, pages 1105 - 1116
    - HOOGENBOOM ET AL., NAT BIOTECHNOL, (2005), vol. 23, page 1105
    - BINZ ET AL., NAT BIOTECHNOL, (2005), vol. 23, page 1247
    - LUNDBLAD; BRADSHAW, BIOTECHNOL. APPL. BIOCHEM., (1997), vol. 26, pages 143 - 151
    - HOLLIGER; HUDSON, NATURE BIOTECHNOLOGY, (2005), vol. 23, no. 9, pages 1126 - 1136
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.